Publications by authors named "Anita Goertz"
Aims/hypothesis: To assess the cost-effectiveness of rosiglitazone in combination with other oral agents for the treatment of overweight and obese patients with type 2 diabetes in Germany.
Methods: The Diabetes Decision Analysis of Cost--type 2 model was adapted for clinical practice and healthcare financing rules in Germany. The model was calibrated using Cost of Diabetes in Europe Type 2 study data and national statistics.
Objectives: The credibility of models rests on their validity. An age-structured decision analytic model, Economic Varicella Vaccination Tool for Analysis (EVITA), has been developed to examine the epidemiologic and economic effects of universal varicella (chicken pox) vaccination in Germany. EVITA combines a varicella transmission module describing the spread of infection in a population over time with a second module describing the course of disease in case of an infection.
View Article and Find Full Text PDFVaricella is a potentially serious infection not only in immunocompromised individuals but also in otherwise healthy adults and children. Vaccination plays an important role in preventing the disease and its sequelae. A universal vaccination in childhood is expected to reduce substantially the number of uncomplicated cases of varicella and decrease the number of complicated cases requiring hospitalisation.
View Article and Find Full Text PDFObjective: The Costs of Diabetes in Europe-Type 2 study (CODE-2, SmithKline Beecham plc) measures costs of managing patients with type 2 diabetes mellitus in Germany. The aim of this analysis was to assess the uncertainty of these estimates.
Design And Setting: The German study arm was based on a sample of 809 patients with type 2 diabetes registered in general practices.